We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Globally, the market for biologic drugs is growing significantly, due to their proven ability to treat major chronic diseases, in particular those found among an increasingly aging population. Cartridge systems are very important in delivering these biologic drugs; they can be used in autoinjectors, pen injectors, and wearable devices. Since biologics drugs are very sensitive, they require highest-quality cartridge components.
Anticipating both technical and market needs, West has designed, and manufactures, components compatible with 3mL ISO glass cartridge barrels, namely NovaPure® cartridge components comprising 3mL cartridge plungers and 8mm lined seals. These components were developed based on Quality-by-Design (QbD) principles. The QbD approach is a systematic, science-based approach to manufacturing that supports the highest levels of process understanding. This includes identification and monitoring of critical process parameters, targeted improvements to optimize critical processes, continuous improvement based on statistical analysis, and a documented product knowledge database.
Key features of NovaPure 3mL cartridge components are:
NovaPure 3mL cartridge components help mitigate risks associated with biologic drug packaging and delivery components, and help to achieve the primary objective of patient safety. For more information click here or contact an Account Manager or Technical Customer Support (TCS) representative.
NovaPure® and FluroTec® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
FluroTec® and B2-coating technologies are licensed from Daikyo Seiko, Ltd.
West is excited to announce an addition to its NovaPure<sup>®</sup> product line — NovaPure 3mL Cartridge components, which include plunger and seal components specifically designed to ensure consistency of delivery for higher-volume injectable drug delivery systems. The components were designed to address specific issues and challenges the pharmaceutical industry faces in bringing innovative injectable drug products to market.
The global pen injector and auto-injector markets have witnessed significant growth due to the increasing demand for self-administration of injectable drugs. Pen injectors and auto-injectors provide a user-friendly and convenient solution for patients to administer medications, contributing to improved patient compliance and overall healthcare outcomes. There are well established traditional market segments that use cartridge-based delivery systems, including dental local anesthesia and diabetes care, as well as human growth hormone and allergy therapies. However, there have been significant developments in the incorporation of cartridges in auto-injectors as supposed to the traditional syringe designs.
Drug delivery via cartridge-based systems has been around for many years, with traditional applications being for the dental and insulin markets. These traditional markets will continue to maintain much of the volume for cartridge-based systems in the future; however, there is an increasing trend toward other therapeutic classes of drugs, such as those that treat auto-immune diseases, that never used cartridges before. This trend, along with the projected growth in the insulin market, indicates substantial overall growth in the cartridge space over the next several years. This Blog discusses the issues driving these trends and the West product portfolio in the cartridge market.
<strong>NovaPure® Components Overview</strong><br /><em>By leveraging nearly 100 years of pharmaceutical packaging knowledge and implementing Quality by Design principles, West has developed the continuously improving NovaPure® elastomer portfolio which can be ideal for all drug product phases.</em>
The market for prefillable syringe systems (PFS) is growing at a rate of approximately 10 percent per year, with cartridge-based systems growing even faster at rates of 13 percent (2013 market outlook, IMS). The predominant areas of growth are within the insulin and biologics therapeutic areas, as well as overall growth within emerging markets.
English
Chinese
